Tulane Cancer Center, Tulane University, New Orleans, LA, USA.
Medical Oncology, Mayo Clinic, Rochester, MN, USA.
Oncologist. 2023 Nov 2;28(11):e1127-e1128. doi: 10.1093/oncolo/oyad240.
Considering recently published data, this letter to the editor highlights the clinical relevance of CDK12 pathogenic or likely pathogenic mutations, noting that Black men have prostate cancers with increased rates of this pathologic alteration. Practitioners should be made aware of recent findings, given that CDK12 mutations are known to be associated with aggressive variants of prostate cancer and that they may confer susceptibility to PD-1 antagonists.
考虑到最近发表的数据，这封给编辑的信强调了 CDK12 致病性或可能致病性突变的临床相关性，并指出黑人男性的前列腺癌中这种病理改变的发生率增加。鉴于 CDK12 突变已知与前列腺癌的侵袭性变异有关，并且它们可能使患者易患 PD-1 拮抗剂，因此应让从业者了解最近的发现。
